source
- FDA advisory panel debates allowing compounding pharmacies to produce seven peptidesThe FDA’s advisory committee spent two days reviewing whether compounding pharmacies should be permitted to manufacture a set of seven peptide products. The discussion involved both committee membe…
- Incyte drops phase-1 JAK2 inhibitor to focus on next-generation candidatesIncyte announced it is abandoning its phase-1 JAK2V617F inhibitor, INCB160058, which was being tested in patients with myeloproliferative neoplasms. The decision was disclosed in the company's sec…